Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: A cohort study

doi:10.12998/wjcc.v7.i14.1814

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 14

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5785)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

297

WORD

134

HTML

2880

Figures (1-1)

285

Tables (1-4)

314

Sum=3910

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

568

Download

1307

Sum=1875

Jul 26, 2019 (publication date) through Feb 12, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Clin Cases. Jul 26, 2019; 7(14): 1814-1824
Published online Jul 26, 2019. doi: 10.12998/wjcc.v7.i14.1814

Table 4 Immunological responses to highly active antiretroviral therapy

	Baseline		24 wk			48 wk			96 wk
	n	mean CD4 (SD)	n	mean CD4 (SD)	P¹ value	n	mean CD4 (SD)	P¹ value	n	mean CD4 (SD)	P¹ value
FDC	80	698.5 (295.3)	80	730.3 (339.7)	0.173	76	707.6 (281.9)	0.717	73	751.7 (289.9)	0.011
Atripla	30	649.7 (285.2)	30	666.3 (278.3)	0.549	29	709.9 (274.8)	0.032	26	715.0 (286.2)	0.02
Truvada	20	678.8 (261.3)	20	658.9 (263.3)	0.639	17	627.1 (224.8)	0.227	17	741.4 (279.2)	0.145
Kivexa	24	740.8 (356.4)	24	823.0 (460.2)	0.107	24	738.1 (341.0)	0.957	24	773.5 (317.2)	0.518
MTR	163	671.6 (268.9)	159	730.4 (282.0)	< 0.001	137	745.2 (281.0)	< 0.001	117	769.0 (269.0)	< 0.001
TDF/3TC/-EFV	46	665.6 (251.3)	43	742.9 (234.1)	0.003	34	746.0 (261.7)	0.002	30	759.9 (245.7)	< 0.001
TDF/3TC	50	665.7 (311.6)	50	735.7 (341.6)	0.003	44	751.8 (336.2)	< 0.001	40	766.8 (311.4)	< 0.001
ABC/3TC	32	675.4 (202.3)	32	733.7 (225.5)	0.06	29	740.7 (211.9)	0.036	28	810.5 (247.2)	< 0.001

¹Mean CD4 difference vs baseline (Fisher’s LSD test). MTR: Multi-tablet regimen; FDC: Fixed dose coformulation.

Citation: Rossi MC, Inojosa WO, Battistella G, Carniato A, Farina F, Giobbia M, Fuser R, Scotton PG. Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: A cohort study. World J Clin Cases 2019; 7(14): 1814-1824
URL: https://www.wjgnet.com/2307-8960/full/v7/i14/1814.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i14.1814